These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39299959)

  • 1. Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase.
    Zhang J; Zhou S; Jiang S; He F; Tu Y; Hu H
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):426. PubMed ID: 39299959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy.
    Zhang J; Shi Y; Zhao M; Hu H; Huang H
    Sci Rep; 2020 Aug; 10(1):14164. PubMed ID: 32843697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
    Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
    Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
    Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Miyaoka M; Kikuti YY; Carreras J; Itou A; Ikoma H; Tomita S; Shiraiwa S; Ando K; Nakamura N
    Pathol Int; 2022 Jan; 72(1):35-42. PubMed ID: 34727403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
    Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
    J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
    Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
    Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the translocation partner in protection against AID-dependent chromosomal translocations.
    Jankovic M; Robbiani DF; Dorsett Y; Eisenreich T; Xu Y; Tarakhovsky A; Nussenzweig A; Nussenzweig MC
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):187-92. PubMed ID: 19966290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
    Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
    J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotylenin A and tyrosine kinase inhibitors synergistically inhibit the growth of chronic myeloid leukemia cells.
    Ikejiri F; Honma Y; Okada T; Urano T; Suzumiya J
    Int J Oncol; 2018 Jun; 52(6):2061-2068. PubMed ID: 29620253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.
    Liu Y; Azizian NG; Dou Y; Pham LV; Li Y
    J Hematol Oncol; 2019 Nov; 12(1):119. PubMed ID: 31752970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
    Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
    Oncotarget; 2017 May; 8(18):29679-29698. PubMed ID: 27557509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
    Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance.
    Soltani I; Douzi K; Gharbi H; Benhassine I; Teber M; Amouri H; Ben Hadj Othman H; Farrah A; Ben Lakhel R; Abbes S; Menif S
    Hematology; 2017 May; 22(4):201-207. PubMed ID: 27825294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.